



HU000032858T2

(19) **HU****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**(11) Lajstromszám: **E 032 858**(13) **T2**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 13 726285**(22) A bejelentés napja: **2013. 04. 12.**(51) Int. Cl.: **C07J 53/00** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20130726285

(86) A nemzetközi (PCT) bejelentési szám:

PCT/IB 13/052918

(97) Az európai bejelentés közzétételi adatai:

EP 2984100 A1 **2014. 10. 16.**

(87) A nemzetközi közzétételi szám:

WO 14167386

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2984100 B1 **2017. 04. 05.**

(72) Feltaláló(k):

LENNA, Roberto, I-20010 S. Giorgio Su Legnano (IT)
BARBIERI, Francesco, I-20813 Bovisio Masciago (IT)
LUONI, Maria Giovanna, I-21010 Cardano Al Campo (IT)
NOSEDA, Monica, I-22100 Como (IT)

(73) Jogosult(ak):

Industriale Chimica S.R.L., 20145 Milano (IT)

(74) Képviselő:

Danubia Szabadalmi és Jogi Iroda Kft.,
Budapest

(54)

Eljárás drospirenone előállítására

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 984 100 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
05.04.2017 Bulletin 2017/14

(21) Application number: **13726285.3**

(22) Date of filing: **12.04.2013**

(51) Int Cl.:
C07J 53/00 (2006.01)

(86) International application number:
PCT/IB2013/052918

(87) International publication number:
WO 2014/167386 (16.10.2014 Gazette 2014/42)

(54) **PROCESS FOR THE PREPARATION OF DROSPIRENONE**

VERFAHREN ZUR HERSTELLUNG VON DROSPIRENON

PROCÉDÉ DE PRÉPARATION DE DROSPIRÉNONE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(43) Date of publication of application:
17.02.2016 Bulletin 2016/07

(73) Proprietor: **Industriale Chimica S.R.L.**
20145 Milano (IT)

(72) Inventors:
• **LENNA, Roberto**
I-20010 S. Giorgio Su Legnano (IT)
• **BARBIERI, Francesco**
I-20813 Bovisio Masciago (IT)
• **LUONI, Maria Giovanna**
I-21010 Cardano Al Campo (IT)

• **NOSEDA, Monica**
I-22100 Como (IT)

(74) Representative: **Palladino, Saverio Massimo et al**
Notarbartolo & Gervasi S.p.A.
Corso di Porta Vittoria, 9
20122 Milano (IT)

(56) References cited:
EP-A2- 1 571 153 WO-A1-2010/146042
CN-A- 101 503 455 US-B1- 6 933 395

• **SCHULTZ MITCHELL J ET AL: "A convenient
palladium-catalyzed aerobic oxidation of
alcohols at room temperature.", CHEMICAL
COMMUNICATIONS (CAMBRIDGE, ENGLAND)
21 DEC 2002, no. 24, 21 December 2002
(2002-12-21), pages 3034-3035, XP002717404,
ISSN: 1359-7345**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


EP 2 984 100 B1

Description**Field of the Invention**

[0001] The present invention relates to the field of processes for the synthesis of steroids and, in particular, to a process for preparing drospirenone on an industrial scale.

Background art

[0002] The compound of formula (I) below, whose chemical name is 6 β ,7 β ;15 β ,16 β -dimethylen-3-oxo-17 α -pregn-4-ene-21,17-carbolactone, is commonly referred to as drospirenone:



[0003] Drospirenone is a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity; by virtue of these properties it has long been used for preparing pharmaceutical compositions with contraceptive action for oral administration.

[0004] Various processes are known in the literature for preparing drospirenone.

[0005] The process described in European Patent EP 075189 B1 obtains the final product drospirenone through oxidation under heating of 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylene-5 β -androstane-3 β ,5,17 β -triol with a mixture of pyridine/water/chromium(VI) oxide. This step represents a substantial drawback in the process: in fact, chromium(VI) oxide, like all Cr(VI) compounds, is an established carcinogen, the use of which is subject to such legislative restrictions that the precautions required during use and disposal of this product led to abandonment of the above industrial process.

[0006] A similar situation occurs with the process of US patent 4,416,985, wherein drospirenone is obtained through oxidation under heating of 3 β ,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylene-5 β ,17 α -pregnane-21,17-carbolactone using a mixture of pyridine/water/chromium(VI) oxide.

[0007] Another process for preparing drospirenone is described in European Patent EP 918791 B8; in the process of this document drospirenone is obtained, still from 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylene-5 β -androstane-3 β ,5,17 β -triol, in two distinct steps and by using an oxidant such as e.g. potassium bromate in the presence of ruthenium salts as catalysts, which eventually must be completely removed from the product.

[0008] European patent EP 1828222 B1 discloses a further process, where the oxidation step is carried out using calcium hypochlorite as an oxidant in the presence, as catalyst, of the 2,2,6,6-tetramethylpiperidine-1-oxyl radical or a derivative thereof; in the process of this patent the oxidant is added in portions until completion of the reaction. This process overcomes the disadvantages of the prior art in that calcium hypochlorite is a non-carcinogenic reagent, nor is 2,2,6,6-tetramethylpiperidine-1-oxyl radical a metal catalyst requiring purification of the final product; however, the need for sequential reagent additions and analytical controls in the course of reaction, while being simple, hamper standardized production that should run continuously or nearly so. As a result, the method of this patent too has process drawbacks with regard to industrial production.


[0009] Thus, there is a continuing need for a simple process for drospirenone production which allows to overcome prior art limitations.

[0010] Hence, it is the purpose of the present invention to provide an industrial process which allows preparing drospirenone without using reagents that are either dangerous or whose use is restricted by industry regulations, and minimizing operator intervention during the process itself.

Summary of the invention


[0011] This purpose is achieved by the present invention, which relates to a process for the production of drospirenone comprising the single-step conversion of a compound selected from 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylen-

5 β -androstane-3 α ,5,17 β -triol and 3(3,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylen-5 β ,17 α -pregna-21,17-carbolactone using gaseous oxygen in the presence of a compound of palladium in the +2 oxidation state, an organic base and molecular sieves in an organic solvent inert under the reaction conditions, at a temperature between 60 and 140 °C. In case of using 17 α -(3-hydroxypropyl)-6 β ,7,15 β ,16 β -dimethylen-5 β -androstane-3 β ,5,17 β -triol, having formula (II) below, the compound can be in mixture with one or both of its lactols, as described in Example 6 of patent EP 1828222 B1 above. The reaction scheme (reaction scheme 1) is as follows, where lactols are shown in parentheses to indicate that they may or may not be present, and the symbol $\sim$ in the formula of lactols indicates that the -OH group can be found either above or below the molecule plane (i.e., in β - or α -configuration, respectively):



[0012] Said reaction allows obtaining drospirenone directly, in a single process step, eliminating the need for subsequent additions of further reagents to complete the conversion.

[0013] In case of using 3 β ,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylen-5 β ,17 α -pregna-21,17-carbolactone (of formula (III) below) as starting compound, the reaction takes place according to the following scheme (reaction scheme 2):



[0014] Features and advantages of the present process will be apparent from the following detailed description.

[0015] WO-A-2010/146042, EP-A-1,571,153 and US-A-6,933,395 also disclose the conversion of compound (III) to compound (I) (Drospirenone), using different catalysts and stoichiometric oxidants to those envisaged in the process of the present invention.

Detailed description of the invention

[0016] The Applicant has developed an extremely simple novel process, which allows obtaining drospirenone from 17 α -(3-hydroxypropyl)-6 β ,7 β ,15 β ,16 β -dimethylen-5 β -androstane-3 β ,5,17 β -triol (II) or from 3 β ,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylen-5 β ,17 α -pregna-21,17-carbolactone (III) using oxygen in the presence of a system comprising a compound of palladium in the +2 oxidation state, an organic base, and molecular sieves in a non-oxidizable organic solvent.

[0017] The first possible reaction substrate of the present process, i.e. the compound 17 α -(3-hydroxypropyl)-6 β ,7 β ,15 β ,16 β -dimethylen-5 β -androstane-3 β ,5,17 β -triol (II) (or a mixture thereof with the corresponding lactols) can be obtained from commercially available products using procedures known to the person skilled in the art. Preferably, said compound is obtained according to steps a) to f) of the process described in patent EP 1828222 B1.

[0018] The second possible reaction substrate of the process, i.e. the compound 3 β ,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylen-5 β ,17 α -pregna-21,17-carbolactone (III), can be obtained according to the procedure described in Example 5(b) of US patent 4,416,985.

[0019] Reaction conditions as described in the following apply regardless of whether one starts from compound (II) or from compound (III).

[0020] The first component of the oxidizing system of the invention is gaseous oxygen.

[0021] Gaseous oxygen gas can be supplied into the reaction vessel as pure oxygen, air, or a synthetic mixture of oxygen with an inert gas (e.g. the so-called synthetic air, which is widely used in the medical field); oxygen, in any of the above forms, can be used under static conditions, i.e. within a closed container in oxygen or oxygen-containing atmosphere, or under mild flow conditions in the same gaseous atmosphere. Working pressure is between room pressure (1 bar) and 10 bar.

[0022] The second component of the oxidizing system is a derivative of palladium in the +2 oxidation state, which is used in amounts by weight ranging from 1% to 100% with respect to the oxidation substrate.

[0023] Examples of palladium compounds suitable for the purposes of the invention include acetate ($\text{Pd}(\text{C}_2\text{H}_3\text{O}_2)_2$), acetylacetonate ($\text{Pd}(\text{C}_5\text{H}_7\text{O}_2)_2$), trifluoroacetate ($\text{Pd}(\text{C}_2\text{O}_2\text{F}_3)_2$), hexafluoroacetylacetonate ($\text{Pd}(\text{C}_5\text{HO}_2\text{F}_6)_2$), propionate ($\text{Pd}(\text{C}_3\text{H}_5\text{O}_2)_2$), chloride (PdCl_2), bromide (PdBr_2), iodide (PdI_2), cyanide ($\text{Pd}(\text{CN})_2$), nitrate ($\text{Pd}(\text{NO}_3)_2$), sulfide (PdS), oxide (PdO) and hydroxide ($\text{Pd}(\text{OH})_2$); among those compounds acetate is preferred, which will also be referred to hereinafter as $\text{Pd}(\text{OAc})_2$, the common abbreviation used in chemistry.

[0024] The third component of the oxidizing system is an organic base which can be selected from: pyridine and its alkyl derivatives, triethylamine, aniline, pyrrolidine, DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene), DBN (1,5-Diazabicyclo[4.3.0]non-5-ene), and cyclic compounds containing two or more nitrogen atoms, both aromatic and non-aromatic; the preferred base is pyridine. The amount by weight of the organic base used is at least 0.5-fold compared with the amount of palladium compound, and preferably between 0.5 and 25 times as much as the amount by weight of said compound.

[0025] Molecular sieves that can be used are those of common commercial availability with pore diameter of 3, 4 and 5 Angstroms, preferably 3 Angstrom-type (3A sieves) both as fine powder and in form of beads or pellets.

[0026] As a solvent for the reaction an organic solvent can be used that is necessarily inert under reaction conditions, with boiling point of at least 60 °C. Such a solvent can be selected from methyl t-butyl ether, ethyl acetate, isopropyl acetate, butyl acetate, heptane, hexane, cyclohexane, toluene, xylene, 1,1-dichloroethane, 1,2-dichloroethane, 1,1,2-trichloroethane, tetrachloroethylene, methyl ethyl ketone, methyl isobutyl ketone, acetonitrile, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, chlorobenzene, N-methyl-pyrrolidone or mixtures thereof.


[0027] The reaction can be carried out at a temperature ranging between 60 and 140 °C, preferably between 80 and 120 °C, for a period of time between 18 and 72 hours, preferably between 20 and 60 hours.

[0028] Crude drospirenone as obtained through the present process can be purified by techniques known to those skilled in the art and disclosed in publications and patents; for example, purification can be achieved by crystallization from isopropyl acetate, as described in patent EP 1828222 B1, or by chromatography as described in EP 75189.

[0029] Potential formation of 1,2-dehydrodrospirenone as an impurity resulting from dehydrogenation of drospirenone positions 1 and 2 can be easily overcome by converting this impurity back into drospirenone through hydrogenation with palladium on carbon in an organic solvent such as tetrahydrofuran; hydrogenation can be performed on the reaction mixture as such after oxygen removal or on the recovered product.

[0030] Alcohol oxidation by $\text{Pd}(\text{OAc})_2$ is known and described in the paper "Palladium(II)-Catalyzed Oxidation of Alcohols to Aldehydes and Ketones by Molecular Oxygen", T. Nishimura et al., J. Org. Chem. 1999, 64, 6750-6755. After reading this paper, however, a chemist with the aim of synthesizing drospirenone from one of the starting compounds of formula (II) or (III) above, would not have been directed to apply the method described in said paper.

[0031] In fact, the process leading to drospirenone formation from intermediate (II) involves three oxidation steps, one cyclization and one dehydration that have to occur in a specific order to yield the desired compound, as depicted in the diagram below:




[0032] In particular, the tertiary OH group in position 17 should not be subjected to dehydration to generate the lactone ring whereas that in position 5 should be subjected to dehydration but only after oxidation of the secondary OH group in position 3. "Early" dehydration of OH group in position 5 would lead to the well-known formation of a diene, as described in the paper "Synthesis of α,β -unsaturated carbonyl compounds by palladium(II)-catalyzed dehydrosilylation of silyl enol ethers", Y. Ito et al., J. Org. Chem. 1978, Vol 43 (5) on page 1021, entry 12.

[0033] The above mentioned paper by T. Nishimura *et al.* discloses in Table 3 examples of aliphatic primary alcohols oxidation, leading exclusively to aldehydes. Table 4 in the paper shows examples of oxidation of diols into lactones; in particular symmetrical diols (entry 1, 2, 3) and an asymmetric diol (entry 4); examples relevant to the present invention are not disclosed, i.e. relating to oxidation of an asymmetrical diol wherein one of the two OH groups is tertiary and thus subject to reactions of tertiary alcohols, including dehydration. Table 5 in the paper shows oxidation of secondary alcohols. Example 7 relates to a steroid in which however the only functional group is the OH group in position 3. Here again, for example, there are no tertiary OH groups, which however are found in compound (II) of the present invention in positions 5 and 17. On page 6753 the authors focus on limitations of the oxidizing system described therein. Interestingly, a small structural difference entails unpredictable reactivity changes resulting in a low reaction rate and the formation of numerous by-products, as can be seen from a comparison discussed by the authors between the behavior observed in examples 6 and 7 of table 6 and molecule 5 in Figure 2, as well as from comparison of molecule 6 in Figure 2 with entry 10 in table 2. In addition, according to the authors, molecule 2 in Figure 2 is not subject to oxidation: it is readily apparent that in molecule 2, which does not undergo oxidation under the conditions as described in the paper, there is a C₅ lactone ring that can also be found in the compounds according to the present invention. Finally, on page 6751 of the paper, the catalyst is reported to be deactivated if the oxidation reaction is conducted at the boiling point of toluene, i.e. T = 110-111 °C; by contrast, the present inventors noted that in the case of the invention not only this phenomenon does not take place, but an oxidation reaction carried out in toluene at a temperature ranging between 100 °C and the solvent boiling point is faster than when carried out at temperatures below 100 °C. For all the above reasons, the skilled artisan would have not been motivated to apply the teaching from the paper by Nishimura *et al.* for the purposes of the present invention.

[0034] In contrast to the disclosures in European Patent EP 182822 B1 and EP 918791 B8, in the present invention all reagents are loaded into the reaction container in a single step, without the need for further action in the course of the reaction, and all the above reactions take place over a single process phase.

[0035] The invention will be further illustrated by the following examples that are provided by way of illustration and are not intended to be limiting of the present invention. The reagents used in the examples are of common commercial availability and are used without prior purification.


EXAMPLE 1**[0036]**

[0037] To a 50 ml flask at room temperature, 224 mg $\text{Pd}(\text{OAc})_2$ (1 mmol), 10 ml toluene, 0.26 ml pyridine (255 mg) and 500 mg molecular sieves 3A are added. It is heated to 80 °C in oxygen atmosphere for 10 minutes.

[0038] Next 500 mg of 93% 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylene-5 β -and rostan-3 β ,5,17 β -triol (II) are added. The reaction mixture is placed under stirring at 80-85 °C still in oxygen atmosphere for 16 h.

[0039] After this time, the organic phase is filtered on paper by washing the filter with methylene chloride and dry concentrated by distillation under reduced pressure (using a rotavapor apparatus).

[0040] The crude product following silica gel chromatography and drying to constant weight yields 346 mg drosiprenone (HPLC purity as measured at 245 nm being 99.01%).

EXAMPLE 2**[0041]**

[0042] To a 1-liter flask at room temperature, 1.3 g $\text{Pd}(\text{OAc})_2$, 300 ml toluene, 7.8 ml pyridine (7.65 g) and 15 g molecular sieves 3A are added.

[0043] It is heated to 80 °C, internal pressure is adjusted first to 4 bar with nitrogen then to 4.5 bar with oxygen. The reaction is stirred under these conditions for 20 minutes while maintaining overall pressure at 4.5 bar using oxygen.


[0044] Next 15 g of 93% 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylene-5 β -androstan-3 β ,5,17 β -triol (II) are added. The reaction mixture is kept under agitation at 80 °C still in oxygen/nitrogen atmosphere at 4.5 bar for 64 h.

[0045] The organic phase is filtered by washing the filter with methylene chloride and dry concentrated (distillation on a rotavapor apparatus).

[0046] The crude product is crystallized using isopropyl acetate yielding after drying to constant weight 7.5 g drosiprenone.

[0047] From mother liquors of crystallization another 1.5 g drosiprenone are recovered by chromatography.

EXAMPLE 3**[0048]**



[0049] To a 50 ml flask at room temperature, 22 mg $\text{Pd}(\text{OAc})_2$, 12 ml toluene, 0.4 ml (392 mg) pyridine and 1 g molecular sieves 3A are added.

[0050] It is heated to 80 °C in oxygen atmosphere for 10 minutes.


[0051] Next 772 mg 3 β ,5-dihydroxy-6 β ,7 β ;15 β ,16 β -dimethylen-5 β ,17 α -pregna-21,17-carbolactone (III) are added. The reaction mixture is placed under stirring at 80 °C still in oxygen atmosphere for 36 h.

[0052] The organic phase is filtered on paper by washing the filter with methylene chloride and dry concentrated (distillation on a rotavapor apparatus).

[0053] The crude product following silica gel chromatography and drying to constant weight yields 601 mg drospirenone (HPLC purity as measured at 245 nm being 98.04%).

EXAMPLE 4

[0054]



[0055] To a 2 liter flask at room temperature, 1.4 g $\text{Pd}(\text{OAc})_2$, 1 liter toluene, 26.1 ml pyridine (25.6 g) and 50 g molecular sieves 3A in powder form are added. It is heated to 80 °C in oxygen atmosphere. The mixture is stirred under these conditions for 10 minutes while maintaining oxygen atmosphere.

[0056] Next 50 g of 93% 17 α -(3-hydroxypropyl)-6 β ,7 β ;15 β ,16 β -dimethylene-5 β -androstan-3 β ,5,17 β -triol (II) are added.


[0057] The reaction mixture is kept under agitation at 85 °C still in oxygen atmosphere for 64 h.

[0058] The organic phase is filtered by washing the filter with toluene and dry concentrated (distillation on a rotavapor apparatus).

[0059] The residue is crystallized using isopropyl acetate yielding 32.1 g drospirenone. From mother liquors of crystallization another 4.5 g drospirenone are recovered by chromatography.

EXAMPLE 5

[0060]



[0061] To a 250 ml flask at room temperature, 0.14 g Pd(OAc)₂, 100 ml toluene, 2.6 ml (2.55 g) pyridine and 5 g molecular sieves 3A in powder form are added. It is heated to 80 °C in oxygen atmosphere. The mixture is stirred under these conditions for 10 minutes while maintaining oxygen atmosphere.

[0062] Next 5 g of 93% 17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-5β-androstan-3β,5,17β-triol (II) are added. The reaction mixture is kept under agitation at 100-110 °C still in oxygen atmosphere for 64 h (dark slurry).

[0063] The organic phase is filtered by washing the filter with toluene and dry concentrated (distillation on a rotavapor apparatus).

[0064] The residue is crystallized with isopropyl acetate yielding 3.1 g drospirenone, which, at HPLC analysis, show the presence of 1,2-dehydrodrospirenone as the major impurity.


[0065] The sample is hydrogenated in 30 ml tetrahydrofuran in the presence of 5% palladium on carbon (100 mg) while maintaining an excess hydrogen pressure of 1 to 1.5 bar at T= 5 °C.

[0066] After reaction completion the catalyst is filtered and the solvent removed under reduced pressure.

[0067] Recovery is 2.96 g drospirenone showing an amount of 1,2-dehydrodrospirenone lower than 0.10 % based on further HPLC analysis.

EXAMPLE 6

[0068]



[0069] To a 3 liter flask at room temperature 1.4 g Pd(OAc)₂, 1 liter butyl acetate, 26.1 ml pyridine (25.6 g) and 50 g molecular sieves 3A in pellet form are added. It is heated to 80 °C in oxygen atmosphere. The mixture is stirred under these conditions for 20 minutes while maintaining oxygen atmosphere.


[0070] Next 50 g of 93% 17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-5β-androstan-3β,5,17β-triol (II) are added. The reaction mixture is kept under agitation at 80 °C still in oxygen atmosphere for 64 h (yellow slurry).

[0071] The organic phase is filtered by washing the filter with toluene and dry concentrated (distillation on a rotavapor apparatus).

[0072] The residue is crystallized using isopropyl acetate yielding 33.1 g drospirenone. From mother liquors of crystallization another 4.1 g drospirenone are recovered by chromatography.

Claims

1. Process for the preparation of drospirenone (I) comprising the single-step conversion of a compound selected from 17α-(3-hydroxypropyl)-6β,7β;15β,16β-dimethylene-5β-androstan-3β,5,17β-triol (II), alone or in a mixture with its lactols, and 3β,5-dihydroxy-6β,7β;15β,16β-dimethylene-5β,17α-pregna-21,17-carbolactone (III):




using oxygen gas in the presence of a palladium compound having the +2 oxidation state, an organic base and molecular sieves in an organic solvent inert under the reaction conditions, at a temperature between 60 and 140 °C.

2. Process according to claim 1, wherein oxygen is used in form of pure oxygen, air, or mixtures of an inert gas and oxygen at a pressure between 1 and 10 bar.
3. Process according to any one of the preceding claims, wherein said palladium compound is selected from acetate ($\text{Pd}(\text{C}_2\text{H}_3\text{O}_2)_2$), acetylacetonate ($\text{Pd}(\text{C}_5\text{H}_7\text{O}_2)_2$), trifluoroacetate ($\text{Pd}(\text{C}_2\text{O}_2\text{F}_3)_2$), hexafluoroacetylacetonate ($\text{Pd}(\text{C}_5\text{HO}_2\text{F}_6)_2$), propionate ($\text{Pd}(\text{C}_3\text{H}_5\text{O}_2)_2$), chloride (PdCl_2), bromide (PdBr_2), iodide (PdI_2), cyanide ($\text{Pd}(\text{CN})_2$), nitrate ($\text{Pd}(\text{NO}_3)_2$), sulfide (PdS), oxide (PdO) and hydroxide ($\text{Pd}(\text{OH})_2$).
4. Process according to any one of the preceding claims, wherein said palladium compound is used in amounts by weight ranging from 1% to 100% with respect to compound (II) or compound (III).
5. Process according to any one of the preceding claims, wherein said organic base is selected from pyridine and its alkyl derivatives, triethylamine, aniline, pyrrolidine, DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene), DBN (1,5-Diazabicyclo[4.3.0]non-5-ene), and cyclic compounds containing two or more nitrogen atoms, both aromatic and non-aromatic.
6. Process according to any one of the preceding claims, wherein said organic base is used in amount by weight equal to or greater than 0,5 times the amount of palladium compound used.
7. Process according to claim 6, wherein the amount by weight of organic base is between 0.5 and 25 times as much as the amount of palladium compound used.
8. Process according to any one of the preceding claims, wherein said molecular sieves have a pore diameter between 3 and 5 angstrom.
9. Process according to any one of the preceding claims, wherein said organic solvent inert under reaction conditions is selected from methyl t-butyl ether, ethyl acetate, isopropyl acetate, butyl acetate, heptane, hexane, cyclohexane, toluene, xylene, 1,1-dichloroethane, 1,2-dichloroethane, 1,1,2-trichloroethane, tetrachloroethylene, methyl ethyl ketone, methyl isobutyl ketone, acetonitrile, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, chlorobenzene, N-methyl-pyrrolidone or mixtures thereof.
10. Process according to any one of the preceding claims, wherein said step is carried out for a period of time between 18 and 72 hours.

11. Process according to any one of the preceding claims, wherein said step is carried out with palladium acetate, in the presence of pyridine as an organic base, using molecular sieves with pore diameter of 3 angstrom, at a temperature between 80 and 120 °C, and for a period of time between 20 and 60 hours.

Patentansprüche

1. Verfahren zur Herstellung von Drospirenon (I), aufweisend eine Einstufen-Umwandlung einer Verbindung, ausgewählt aus 17 α -(3-Hydroxypropyl)-6 β ,7 β ,15 β 16 β -Dimethylen-5 β -Androstan-3 β ,5,17 β -Triol (II) allein oder in einer Mischung mit seinen Lactolen und 3 β ,5-Dihydroxy-6 β ,7 β ;15 β ,16 β -Dimethylen-5 β ,17 α -Pregna-21,17-Carbolacton (III):




unter Verwendung von Sauerstoffgas in Gegenwart einer Palladiumverbindung mit der Oxidationsstufe +2, einer organischen Base und Molekularsieben in einem unter den Reaktionsbedingungen bei einer Temperatur zwischen 60 und 140°C inerten organischen Lösungsmittel.

2. Verfahren gemäß Anspruch 1, wobei Sauerstoff in Form von reinem Sauerstoff, Luft oder Mischungen aus einem inerten Gas und Sauerstoff bei einem Druck zwischen 1 und 10 bar verwendet wird.
3. Verfahren gemäß einem der vorigen Ansprüche, wobei die Palladiumverbindung ausgewählt wird aus Acetat ($\text{Pd}(\text{C}_2\text{H}_3\text{O}_2)_2$), Acetylacetonat ($\text{Pd}(\text{C}_5\text{H}_7\text{O}_2)_2$), Trifluoracetat ($\text{Pd}(\text{C}_2\text{O}_2\text{F}_3)_2$), Hexafluoracetylacetonat ($\text{Pd}(\text{C}_5\text{HO}_2\text{F}_6)_2$), Propionat ($\text{Pd}(\text{C}_3\text{H}_5\text{O}_2)_2$), Chlorid (PdCl_2), Bromid (PdBr_2), Iodid (PdI_2), Cyanid ($\text{Pd}(\text{CN})_2$), Nitrat ($\text{Pd}(\text{NO}_3)_2$), Sulfid (PdS), Oxid (PdO) und Hydroxid ($\text{Pd}(\text{OH})_2$).
4. Verfahren gemäß einem der vorigen Ansprüche, wobei die Palladiumverbindung in Gewichtsmengen zwischen 1% und 100% gegenüber der Verbindung (II oder der Verbindung (III)) verwendet wird.
5. Verfahren gemäß einem der vorigen Ansprüche, wobei die organische Base ausgewählt wird aus Pyridin und seinen Alkyderivaten, Triethylamin, Anilin, Pyrrolidin, DBU (1,8-Diazabicyclo[5.4.0]undec-7-en), DBN (1,5-Diazabicyclo[4.3.0]non-5-en) und aromatischen sowie nicht-aromatischen, zyklischen Mischungen, die zwei oder mehr Stickstoffatome enthalten.
6. Verfahren gemäß einem der vorigen Ansprüche, wobei die organische Base in Gewichtsmengen größer gleich dem 0,5-fachen der Menge der verwendeten Palladiumverbindung verwendet wird.
7. Verfahren gemäß Anspruch 6, wobei die Gewichtsmenge der organischen Base zwischen 0,5 und 25 mal der Menge der verwendeten Palladiumverbindung beträgt.

8. Verfahren gemäß einem der vorigen Ansprüche, wobei die Molekularsiebe eine Porengröße zwischen 3 und 5 Angström haben.
9. Verfahren gemäß einem der vorigen Ansprüche, wobei das unter den Reaktionsbedingungen inerte organische Lösungsmittel ausgewählt wird aus Methyl-t-Butyl-Ether, Ethylacetat, Isopropylacetat, Butylacetat, Heptan, Hexan, Cyclohexan, Toluol, Xylol, 1,1-Dichlorethan, 1,2-Dichlorethan, 1,1,2-Trichlorethan, Tetrachlorethylen, Methyl-Ethyl-Keton, Methyl-Isobutyl-Keton, Acetonitril, Dimethylformamid, Dimethylacetamid, Dimethylsulfoxid, Chlorbenzol, N-Methyl-Pyrrolidon oder Mischungen davon.
10. Verfahren gemäß einem der vorigen Ansprüche, wobei die Stufe zwischen 18 und 72 Stunden durchgeführt wird.
11. Verfahren gemäß einem der vorigen Ansprüche, wobei die Stufe mit Palladiumacetat in Gegenwart von Pyridin als organische Base durchgeführt wird, unter Verwendung von Molekularsieben mit einer Porengröße von 3 Angström, bei einer Temperatur zwischen 80 und 120°C und für eine Dauer von 20 bis 60 Stunden.

Revendications

1. Procédé de préparation de drospirénone (I) comprenant la conversion en une seule étape d'un composé choisi entre le 17 α -(3-hydroxypropyl)-6 β ,7 β ,15 β ,16 β -diméthylène-5 β -androstane-3 β ,5,17 β -triol (II), seul ou dans un mélange avec ses lactols, et la 3 β ,5-dihydroxy-6 β ,7 β ,15 β ,16 β -diméthylène-5 β ,17 α -pregna-21,17-carbolactone (III) :



à l'aide d'oxygène gazeux en présence d'un composé de palladium se trouvant à l'état d'oxydation 2+, d'une base organique et de tamis moléculaires dans un solvant organique inerte dans les conditions réactionnelles, à une température comprise entre 60 et 140 °C.

2. Procédé selon la revendication 1, dans lequel l'oxygène est utilisé sous forme d'oxygène pur, d'air ou de mélanges d'un gaz inerte et d'oxygène à une pression comprise entre 1 et 10 bars.
3. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit composé de palladium est choisi parmi l'acétate ($\text{Pd}(\text{C}_2\text{H}_3\text{O}_2)_2$), l'acétylacétionate ($\text{Pd}(\text{C}_5\text{H}_7\text{O}_2)_2$), le trifluoroacétate ($\text{Pd}(\text{C}_2\text{O}_2\text{F}_3)_2$), l'hexafluoroacétylacétionate ($\text{Pd}(\text{C}_5\text{HO}_2\text{F}_6)_2$), le propionate ($\text{Pd}(\text{C}_3\text{H}_5\text{O}_2)_2$), le chlorure (PdCl_2), le bromure (PdBr_2), l'iodure (PdI_2), le cyanure ($\text{Pd}(\text{CN})_2$), le nitrate ($\text{Pd}(\text{NO}_3)_2$), le sulfure (PdS), l'oxyde (PdO) et l'hydroxyde ($\text{Pd}(\text{OH})_2$).
4. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit composé de palladium est utilisé dans des quantités en poids allant de 1 % à 100 % par rapport au composé (II) ou au composé (III).

EP 2 984 100 B1

5. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite base organique est choisie parmi la pyridine et ses dérivés alkylés, la triéthylamine, l'aniline, la pyrrolidine, le DBU (1,8-diazabicyclo[5.4.0]undéc-7-ène), le DBN (1,5-diazabicyclo[4.3.0]non-5-ène), et des composés cycliques contenant deux atomes d'azote ou plus, aromatiques ou non aromatiques.
6. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite base organique est utilisée dans une quantité en poids supérieure ou égale à 0,5 fois la quantité de composé de palladium utilisée.
7. Procédé selon la revendication 6, dans lequel la quantité en poids de base organique est entre 0,5 et 25 fois supérieure à la quantité de composé de palladium utilisée.
8. Procédé selon l'une quelconque des revendications précédentes, dans lequel lesdits tamis moléculaires ont un diamètre de pore compris entre 3 et 5 angströms.
9. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit solvant organique inerte dans des conditions réactionnelles est choisi parmi le méthyl t-butyl éther, l'acétate d'éthyle, l'acétate d'isopropyle, l'acétate de butyle, l'heptane, l'hexane, le cyclohexane, le toluène, le xylène, le 1,1-dichloroéthane, le 1,2-dichloroéthane, le 1,1,2-trichloroéthane, le tétrachloroéthylène, la méthyléthylcétone, la méthylisobutylcétone, l'acétonitrile, le diméthylformamide, le diméthylacétamide, le diméthylsulfoxyde, le chlorobenzène, la N-méthyl-pyrrolidone ou leurs mélanges.
10. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite étape s'effectue pendant un laps de temps compris entre 18 et 72 heures.
11. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite étape s'effectue avec de l'acétate de palladium, en présence de pyridine servant de base organique, à l'aide de tamis moléculaires ayant un diamètre de pore de 3 angströms, à une température comprise entre 80 et 120 °C et pendant un laps de temps compris entre 20 et 60 heures.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.


Patent documents cited in the description

- EP 075189 B1 [0005]
- US 4416985 A [0006] [0018]
- EP 918791 B8 [0007] [0034]
- EP 1828222 B1 [0008] [0011] [0017] [0028] [0034]
- WO 2010146042 A [0015]
- EP 1571153 A [0015]
- US 6933395 A [0015]
- EP 75189 A [0028]

Non-patent literature cited in the description

- **T. NISHIMURA et al.** Palladium(II)-Catalyzed Oxidation of Alcohols to Aldehydes and Ketones by Molecular Oxygen. *J. Org. Chem.*, 1999, vol. 64, 6750-6755 [0030]
- **Y. ITO et al.** Synthesis of α,β -unsaturated carbonyl compounds by palladium(II)-catalyzed dehydrosilylation of silyl enol ethers. *J. Org. Chem.*, 1978, vol. 43 (5), 1021 [0032]

1. Eljárás drospirenone (I) előállítására, amely magában foglalja egy, 17 α -(3-hidroxipropil)-6 β ,7 β ,15 β ,16 β -dimetilén-5 β -androsztán-3 β ,5,17 β -triol (II) önmagában vagy laktoljaival összekeverve és 3 β ,5-dihidroxí-6 β ,7 β ;15 β ,16 β -dimetilén-5 β ,17 α -pregna-21,17-karbolakton (III) közül kiválasztott vegyület egy-lépéses átalakítását:



oxigéngáz alkalmazásával +2 oxidációs állapotú palládium-vegyület, egy szerves bázis és molekulasziták jelenlétében egy, a reakciókörülményekkel szemben inert szerves oldószerben 60°C és 140 °C közötti hőmérsékleten.

2. Az 1. igénypont szerinti eljárás, ahol az oxigént tiszta oxigén, levegő vagy inert gáz és oxigén keveréke formájában használjuk 1 bar és 10 bar közötti nyomáson.

3. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett palládium-vegyület acetát (Pd(C₂H₃O₂)₂), acetilacetónát (Pd(C₅H₇O₂)₂), trifluoracetát (Pd(C₂O₂F₃)₂), hexafluoracetilacetónát (Pd(C₅HO₂F₆)₂), propionát (Pd(C₃H₅O₂)₂), klorid (PdCl₂), bromid (PdBr₂), jodid (PdI₂), cianid (Pd(CN)₂), nitrát (Pd(NO₃)₂), szulfid (PdS), oxid (PdO) és hidroxid (Pd(OH)₂) közül van kiválasztva.

4. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett palládium-vegyületet a (II) vegyületre vagy a (III) vegyületre vonatkoztatva 1% - 100 tömeg% tartományba eső mennyiségben használjuk.

5. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett szerves bázist piridin és ennek alkil-származékai, trietil-amin, anilin, pírrolidin, DBU (1,8-diazabicyclo[5.4.0]undec-7-én), DBN (1,5-diazabicyclo[4.3.0]non-5-én) és két vagy több nitrogénatomot tartalmazó mind aromás, mind nem-aromás gyűrűs vegyület közül van kiválasztva.



6. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett szerves bázist az alkalmazott palládium-vegyület mennyiségével azonos vagy annak 0,5-szörösénél nagyobb tömegben kifejezett mennyiségben használjuk.

7. A 6. igénypont szerinti eljárás, ahol a szerves bázis tömegben kifejezett mennyisége az alkalmazott palládium-vegyület mennyiségének 0,5-szöröse és 25-szöröse közötti.

8. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett molekulasziták pórusátmérője 3 és 5 Angström közötti.

9. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett, reakciókörülményekkel szemben inert szerves oldószer metil-terc-butil-éter, etil-acetát, izopropil-acetát, butil-acetát, heptán, hexán, ciklohexán, toluol, xilén, 1,1-diklóretán, 1,2-diklóretán, 1,1,2-triklóretán, tetraklóretilén, metil-etil-keeton, metil-izobutil-keeton, acetonitril, dimetilformamid, dimetilacetamid, dimetil-szulfoxid, klórbenzol, N-metil-pirrolidon vagy ezek keverékei közül van kiválasztva.

10. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett lépést 18 óra és 72 óra között időtartamig végezzük.

11. Az előző igénypontok bármelyike szerinti eljárás, ahol az említett lépést palládium-acetáttal végezzük szerves bázisként piridin jelenlétében, 3 Angström pórusátmérőjű molekulasziták alkalmazásával 80°C és 120°C közötti hőmérsékleten 20 óra és 60 óra közötti időtartamig.